Phase 1 N=16 A Study of Single and Multiple Doses of ALXN1210 in Healthy, Adult Japanese Participants
Healthy
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 2; 3; 8 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=66 Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus
Diabetes Mellitus Type 2
Primary: Number of Participants With Treatment Emergent Treatment-Related Adverse Events — 5; 2; 6; 6 Participants
Phase 1 N=20 TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma
Gastric Adenocarcinoma · GastroEsophageal Cancer
Primary: Percentage of Participants With Progression-free Survival at 6 Months — 40 percent of participants
Phase 1 N=35 A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Primary: Number of Participants With Dose Limiting-Toxicities (DLTs) After SC Administration — 0; 1; 1; 0 Participants
Phase 1 N=18 A Study of Multiple-ascending Doses of IW-3300 in Healthy Subjects
Healthy Volunteers
Primary: Incidence of Treatment-Emergent Adverse Events (TEAEs) — 3; 3; 2 Participants
Phase 1 N=36 A Study of Soticlestat in Adults With Liver Failure Compared to Those With Normal Liver Function
Hepatic Impairment · Healthy Volunteers
Primary: Cmax: Maximum Observed Plasma Concentration for Soticlestat — 3230; 3666; 1435; 1705 nanogram per milliliter (ng/mL)
Phase 1 N=97 A Study of Lasmiditan in Healthy Volunteers
Healthy
Primary: Part 1 Pharmacokinetics (PK): Maximum Concentration (Cmax) of Dabigatran to Assess P-glycoprotein (P-gp) Activity. — 138; 168 nanograms/milliliter (ng/mL)
Phase 1 N=18 Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia.
Leukemia Lymphoblastic, Acute · Acute Myeloid Leukemia · Neoplasm Recurrent
Primary: Maximum Feasible Dose of Clofarabine — 52 mg/m^2
Phase 1 N=16 Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)
Breast Neoplasm · Breast Neoplasm, Male · Triple Negative Breast Cancer
Primary: Establish the Safety of the IRX-2 Regimen When Administered Pre-operatively in Early Stage Breast Cancer (ESBC) Patients — 0; 0 Participants
Phase 1 N=29 A Study of Mirikizumab in Participants With Plaque Psoriasis
Psoriasis
Primary: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Midazolam — 4.07; 4.46 Nanograms per millilitre (ng/mL)
Phase 1 N=60 A Study of Mirikizumab in Healthy Chinese Participants
Healthy
Primary: Number of Participants With One or More Drug-Related Treatment-Emergent Adverse Events (TEAEs) — 1; 3; 4; 1 participants
Phase 1 N=60 A Study to Compare Two Different Formulations of Mirikizumab in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab — 12.7; 11.6 micrograms per milliliter (ug/mL)
Phase 1 N=12 Study to Evaluate the Safety, Local and Systemic Tolerability, and Pharmacokinetics of Multiple-Dose Topical Administration of PF-07038124 in Japanese Healthy Participants
Healthy
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 0; 0; 1; 0 Participants
Phase 1 N=66 A Study of Two Formulations of LY3074828 in Healthy Participants
Healthy
Primary: Pharmacokinetics: Maximum Concentration (Cmax) of LY3074828 by Device — 22.2; 18.7 micrograms per milliliter (μg/mL)
Phase 1 N=54 A Study of Two Different Formulations of LY3074828 in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Dose-normalized Area Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (DN-AUC[0-tlast]) of LY3074828…